Am J Transplant, Volume 3, Suppl 5 Archives - Page 127 of 178 - ATC Abstracts

2013 American Transplant Congress
Outcome of Hepatitis B and C Virus Associated Hepatocellular Carcinoma Occurring after Renal Transplantation
N. Kanaan, C. Raggi, E. Goffin, Z. Hassoun
Nephrology, Cliniques Universitaires Saint Luc, Brussels, Belgium; Gastroenterology, Cliniques Universitaires Saint Luc, Brussels, Belgium
Background: Chronic hepatitis B (HBV) and C (HCV) virus infections are causes of morbidity and mortality in kidney transplant recipients (KTR). Immunosuppressive agents enhance HBV…
2013 American Transplant Congress
ABO Incompatible Kidney Transplantation Using Subcutaneous Alemtuzumab for Induction and No Post Transplant Plasmapheresis
R. Villicana, J. Kahwaji, A. Peng, R. Najjar, S. Jordan, A. Vo
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
Introduction: Blood group incompatibility (ABOi) is a significant barrier to living donor (LD) kidney transplantation (ktx). We describe our ABOi kidney tx desensitization protocol which…
2013 American Transplant Congress
Arachidonate Lipoxygenase Controls the Suppressive Function of Myeloid Derived Suppressor Cells
M. Burns, J. Ochando
The Mount Sinai School of Medicine, New York, NY
Background: Myeloid derived suppressor cells (MDSC) are myeloid cells with suppressive function, a definition that reflects both their origin and function. MDSC represent a heterogeneous…
2013 American Transplant Congress
Effect of Proteasom Inhibition with Bortezomib Associated with Steroids on the Decrease of HLA Antibodies before Transplantation
O. Aubert, C. Suberbielle, R. Gauthe, E. Nnang, H. Francois, A. Durrbach
Nephrology Department, IFRNT, Bicetre Hospital, Le Kremlin Bicetre, France; U1014, INSERM, Villejuif, France; Histocompatibility Lab, APHP, Paris, France; Rouen Hospital, Rouen, France
IntroductionCurrently, all proposed treatments for desensitivation are often ineffective or transient (plasmapheresis, intravenous immunoglobulin or rituximab) to control the production of antiHLA antibodies by B…
2013 American Transplant Congress
CD4+ but Not CD8+ Memory T Cells Escape Granzyme B Mediated Regulation by DN-Treg
Y. Su, X. Huang, D. Lian, W. Min, A. Jevnikar, Z. Zhang
Matthew Mailing Centre for Translational Transplant Studies, London Health Sciences Centre, London, ON, Canada; Departments of Medicine, Western University, London, ON, Canada; Departments of Pathology,Microbiology&Immunology, Western University, London, ON, Canada
Memory T cell (Tm) homeostasis is poorly understood and is a critical challenge to controlling transplant rejection. At present there are no effective clinical strategies…
2013 American Transplant Congress
Polymorphism of the Vitamin D Receptor and Risk of New-Onset Diabetes after Transplantation in Hispanic Kidney Transplant Recipients
D. Min, D. Vu, E. Tellez-Corrales, J. Yang, P. Sakharkar, T. Shah, I. Hutchinson
Western University of Health Sciences, Pomona, CA; St. Vincent Medical Center, Los Angeles, CA; National Institute of Transplantation, Los Angeles, CA; Nova Southeastern University, Lauderdale, FL; University of Kansas, Kansas City, KS; Roosevelt University College of Pharmacy, Schaumburg, IL
Background: New-onset diabetes after transplantation (NODAT) is an important metabolic complication that increases risk of cardiovascular disease and is associated with lower allograft and patient…
2013 American Transplant Congress
Role of Graft-Derived MCP1 in Antibody-Mediated Rejection of Cardiac Allografts
T. Abe, C. Su, S. Iida, W. Baldwin III, N. Nonomura, S. Takahara, R. Fairchild
Immunology, Cleveland Clinic, Cleveland, OH; Urology, Osaka University, Suita, Japan; Advanced Technology for Transplantation, Osaka University, Suita, Japan
INTRODUCTION: Macrophages are components of the innate immune response and quickly infiltrate tissues during inflammation. Their role in antibody-mediated rejection (AMR) remains unclear. We have…
2013 American Transplant Congress
Is Liver Transplantation Outcome Worse for HCC Patients Using Organ Donation after Cardiac Death?
G. El-Gazzaz, K. Hashimoto, C. Quintini, D. Kelly, C. Winans, B. Eghtesad, F. Aucejo, K. Abu-Elmagd, J. Fung, C. Miller
Liver Transplant, Cleveland Clinic Foundation, Cleveland, OH
BACKGROUNDDonation after cardiac death (DCD) has been used as potential way to increase donor liver availability. The aim of this study was to compare early…
2013 American Transplant Congress
Long-Term Risk of ESRD Attributable to Live Kidney Donation: Matching with Healthy Non-Donors
A. Muzaale, A. Massie, J. Wainright, M. McBride, M. Wang, D. Segev
Johns Hopkins School of Medicine, Baltimore, MD; United Network of Organ Sharing, Richmond, VA; Johns Hopkins School of Public Health, Baltimore, MD
Background Higher rates of ESRD post-donation have been reported in African-American donors than in white donors, but no studies have compared ESRD incidence in donors…
2013 American Transplant Congress
Early Experience with 3-Month Ciprofloxacin Prophylaxis for BK Infection in Renal Transplantation
S. Patel, R. Knight, L. Moore, A. Lehnert, A. Agbetoba, J. DeVos, A. Gaber
The Methodist Hospital, Houston
BK polyomavirus (BKV) is a significant infection affecting renal transplant recipients. Previous data suggests possible activity of fluoroquinolones against BKV, although their role in preventing…